Towa Pharmaceutical Co., Ltd.
Financial Summary and Earnings Report
The fiscal year ending March 2026 recorded revenues of approximately ¥273.7 billion, operating profit of ¥23.1 billion, and net income of ¥5.2 billion, representing an increase compared to the same period last year. Revenue exceeded the prior year's figure, and profits showed substantial growth.
Key Figures
- Revenue: ¥273.7 billion (YoY +5.4%)
- Operating Income: ¥23.1 billion (YoY -0.6%)
- Net Income: ¥5.2 billion (YoY -72.3%)
AI要約
Summary of Financial Results
Towa Pharmaceutical's fiscal year ending March 2026 reported revenues of approximately ¥273.7 billion (YoY +5.4%), operating income of ¥23.1 billion (YoY -0.6%), and net income of ¥5.2 billion (YoY -72.3%). While revenue increased compared to the previous year, net income decreased significantly. The revenue growth was mainly driven by increased sales of pharmaceuticals domestically and internationally. Although the business scale expanded, the decline in net income is attributed to some increased costs and special losses.
Future Outlook and Investor Impact
The company aims to continue increasing revenues while focusing on cost management and efficiency improvements to enhance profitability. For investors, sustaining revenue growth and working towards profit improvement are key priorities. Progress in research and development expenses and cost reduction initiatives is expected to improve future profitability.
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
